EGFR and non-small cell lung carcinoma: In the phase III MARIPOSA trial, patients with EGFR-mutated NSCLC were randomized to the first-line treatment of osimertinib or amivantamab with lazertinib, which demonstrated a benefit on the PFS in patients with a history of BrMs with amivantamab and lazertinib (HR 0.69, 95% CI 0.53–0.92), although the intracranial ORR and PFS were not described [103].